GSKBy Calypso Research7 min read

GSK plc (GSK) Q4 2025 Earnings Analysis

GSK Delivers a Dose of Growth with $8.5B Cure for Doubts

Key Takeaways

GSK plc (GSK) reported Q4 2025 earnings with revenue of $8.5B, representing a +4.8% year-over-year change. The stock moved +7.3% on earnings day.

The bull case: Bulls see a diversified specialty pipeline, led by long-acting HIV and respiratory assets plus targeted BD, driving resilient growth through LOEs and supporting the reiterated 2031 £40bn+ revenue ambition.

The bear case: Bears worry that HIV LOE headwinds, complex respiratory and oncology launches (Exdensur, BLENREP), and execution risk around R&D simplification and vaccines like Shingrix will prevent GSK from achieving its long-term growth and margin targets.

Financial Highlights

  • Revenue: $8.5B (+4.8% YoY)
  • Gross Profit: $5.9B (69.4% margin, +0.9% YoY)
  • Operating Income: $952M (11.2% margin, +2.6% YoY)
  • Net Income: $628M
  • TTM Revenue: $32.6B

Stock Performance

  • Earnings Day Move: +7.3%
  • Year-to-Date: +19.4%
  • 1-Year Return: +59.8%
  • vs. S&P 500 (since earnings): +19.1%
  • vs. Nasdaq (since earnings): +22.5%

View live GSK data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from GSK plc's Q4 2025 earnings call:

Long-Acting HIV Strategy, Dolutegravir LOE, and the Shape of the HIV Revenue Curve

Sentiment: Positive

"we are on track to select our Q6M treatment regimen in the middle of the year... you'll see us move into Phase II this year. That puts us on track for our commitment, which is the 28 to 30 launch for our Q6M in treatment." — Deborah Waterhouse
"you see a dip in '29 and '30 for the franchise as we face into the largest erosion through the exclusivity loss. And then we come back out into growth in 2031 and beyond... HIV will be a big contributor to GSK's success this decade and into the future." — Deborah Waterhouse

Respiratory Strategy in COPD & Asthma: Portfolio Overlap (Nucala, Exdensur, TSLP, IL‑33, Others)

Sentiment: Positive

"it's a complex disease. It's a heterogeneous disease. And that's why we're placing ourselves across a range of different long-acting mechanisms... the high EO population... is where IL-5 and Exdensur and Nucala are positioned... the intermediate T2 population... that's where we see, for example, our long-acting TSLP starting to play increasingly... and then the low T2 population, and that's where we're positioning IL-33." — Tony Wood
"we're going to resist the temptation as a company to construct a lovely PowerPoint slide that shows how we'll carefully capture this bit and have trade-offs amongst our products... there is a strategic intent here, but we also recognize there's a [indiscernible] Dimension here, in terms of the data that these targets generate, but also the competition gets a vote as well." — Luke Miels

Exdensur Launch Trajectory and Bio‑Naive vs Switch Strategy in Severe Asthma

Sentiment: Positive

"our main objective... is going for bio-naive patients. It's very legitimate to expect there will be some switching... What is more relevant is can Exdensur gain share from patients who would have otherwise started on other agents... there is a huge level of enthusiasm for long-acting 6 monthly dosing." — Nina Mojas
"the positioning is the first and only biologic that delivers ultra-long protection in 2 doses that's landing extremely well when we look at market research and perception." — Luke Miels

BLENREP Relaunch: REMS, Eye‑Care Coordination, and Expected Ramp Curve

Sentiment: Mixed

"the timing of opening the accounts is going to take a bit of time, longer probably than what you would see with an asset that doesn't need that coordination of care... we are actively educating 18,000 eye care professionals... REMS has been a big factor... It has been received very positively. Currently, REMS is not an issue." — Nina Mojas
"if we look at usage right now for BLENREP, it's about 50-50 between academic and community, which our strategy is to focus on the community... the strategy of focusing on the community, building confidence, supporting them to dose the first 5 patients appears to be showing promise... we continue to expect this to be a slow ramp-up." — Luke Miels

2031+ Revenue Ambition (£40bn+) and the Role of Recent BD (Efimosfermin, IDRx, Rapp/Ozureprubart)

Sentiment: Positive

"I’ll just take this opportunity just in case we get any other questions to reiterate the commitment to the 40. And again, I think we have a clear pathway for that." — Luke Miels
"IDRx has included Efimosfermin, together with the earlier stage Hengrui license, PDE34. Rapp obviously has just been announced, so it's not included at all in the LRF. And clearly, we continue, as Luke mentioned, to support our BD to build and continue to build the pipeline." — Julie Brown

Bull Case

Bulls see a diversified specialty pipeline, led by long-acting HIV and respiratory assets plus targeted BD, driving resilient growth through LOEs and supporting the reiterated 2031 £40bn+ revenue ambition.

Bear Case

Bears worry that HIV LOE headwinds, complex respiratory and oncology launches (Exdensur, BLENREP), and execution risk around R&D simplification and vaccines like Shingrix will prevent GSK from achieving its long-term growth and margin targets.

Looking Ahead

Investors will be closely watching GSK plc's next quarterly report for continued execution, particularly around long-Acting HIV Strategy, Dolutegravir LOE, and the Shape of the HIV Revenue Curve. With operating margins at 11.2%, margin trends will remain a focal point. The market's positive reaction on earnings day suggests confidence in management's direction, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was GSK plc's revenue in Q4 2025?

GSK plc reported Q4 2025 revenue of $8.5B, representing a +4.8% year-over-year change.

Did GSK plc beat earnings expectations in Q4 2025?

The stock rose +7.3% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: Bulls see a diversified specialty pipeline, led by long-acting HIV and respiratory assets plus targeted BD, driving resilient growth through LOEs and supporting the reiterated 2031 £40bn+ revenue ambition.

What is the bull case for GSK stock?

The bull case for GSK centers on: Bulls see a diversified specialty pipeline, led by long-acting HIV and respiratory assets plus targeted BD, driving resilient growth through LOEs and supporting the reiterated 2031 £40bn+ revenue ambition.

What is the bear case for GSK stock?

The bear case for GSK centers on: Bears worry that HIV LOE headwinds, complex respiratory and oncology launches (Exdensur, BLENREP), and execution risk around R&D simplification and vaccines like Shingrix will prevent GSK from achieving its long-term growth and margin targets.

How has GSK stock performed since its Q4 2025 earnings?

GSK moved +7.3% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +19.1% since earnings. Year-to-date, the stock has returned +19.4%.

Browse all 400+ earnings reports →

Learn More

Analyze GSK in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for GSK plc and 400+ other stocks, explore the full platform.

Open GSK on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.